Antibody Screening - Unravelling the full potential of entire immune repertoires (millions of B cells) VERAXA´s unique platform can combine the assessment of antibody binding with its functional capabilities in 1 single screening step, using a proprietary droplet-based microfluidic screening workstation.


Biotechnology

Veraxa Biotech

Veraxa Biotech's headquarters in Heidelberg, Germany

Christoph Antz

Christoph Erkel

Yasemin Doeger

Torsten Bürgermeister

Michael Ruppert

Lars Hufnagel

Berthold Hackl

Norbert Windhab

David L. Deck

Heinz Schwer

Jürgen Bauer

Oliver R. Baumann

The Research and Development team at Veraxa Biotech focuses on leveraging innovative methodologies to explore and enhance the capabilities of antibody screening. By integrating cutting-edge techniques in microfluidics and functional assessment, the team members—ranging from scientists to engineers—collaborate to identify and develop novel antibodies with therapeutic potential, thereby driving advancements in immunotherapy and biotechnology.

Research and Development

The Leadership Team at Veraxa Biotech drives strategic direction and operational excellence in the development of their innovative antibody screening platform. Comprising seasoned experts in biotechnology, finance, and technology, this team collaborates to enhance research and development initiatives, ensure effective resource allocation, and propel the company's mission of maximizing the potential of immune repertoires through groundbreaking biotechnological advancements.

Leadership Team

��

Veraxa Biotech

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

��������

Veraxa Biotech

Org chart

Board & advisors

Teams

Research and Development

Leadership Team

Offices

Related companies

��